ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0081

Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies

Massimo Radin1, Alice Barinotti1, Irene Cecchi2, Silvia Grazietta Foddai1, Elena Rubini1, Dario Roccatello1, Elisa Menegatti1 and Savino Sciascia1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

Meeting: ACR Convergence 2021

Keywords: antiphospholipid syndrome, Autoantibody(ies), autoimmune diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Antiphospholipid Syndrome Poster (0069–0083)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in distinguishing various populations of aPL positive patients (with and without lupus anticoagulant – LA) and its association with β2GPI-dependent and anti-phosphatidyl-serine/prothrombin (aPS/PT) antibodies.

Methods: One-hundred-and-eight patients were tested with TGA and divided as follows: 21 patients with aPS/PT IgG/IgM, 29 with aβ2GPI IgG/IgM, 31 with aPS/PT and aβ2GPI IgG/IgM, 27 with aPS/PT and/or aβ2GPI IgM low-titers. Table 1 resumes the clinical characteristics of the APS patients (excluding aPL asymptomatic). Thirty-one healthy donors (HDs) and 24 controls treated with VKA were also included.

Results: The most deranged TGA and LA profile was observed in patients with both aPS/PT and aβ2GPI when compared to those with an isolated positivity for aPS/PT or aβ2GPI and patients with aPS/PT and/or aβ2GPI IgM at low titres (Figure 1). Similarly, patients with aPS/PT and/or aβ2GPI at medium/high titres presented with the higher rate of clinical manifestations.

When comparing the TGA curves of APS patients, asymptomatic aPL positive (aPL+) subjects, HDs and controls treated with VKA, we observed that aPL+ patients (particularly those with a confirmed diagnosis of APS) showed a characteristic profile (Figure 2). Moreover, both in aPL+ subjects and in the control groups we observed a correlation between TGA and LA parameters.

Conclusion: TGA seems a valuable approach to stratify aPL+ patients according to their risk profile. The differences among groups and different populations of autoantibodies specificities obtained from this test can be considered a translational validation of the increased thrombotic risk of patients with triple or tetra aPL positivity.

“Classical” and “Extra-criteria” APS clinical manifestations of each group (considering solely patients with a confirmed diagnosis of APS).

Graphical representation of the differences between TGA and LA profiles between groups.
The differences between groups that reached statistical significance (p<0,05) are indicated in the graph.
(aPS/PT – Anti-phosphatidylserine/prothrombin antibodies; aβ2GPI – Anti-β2-glycoprotein-I antibodies; Ig – Immunoglobulin; tLag – Lag time; tPeak – Time to peak; AUC – Area under the curve; sctScreen – Silica Clotting Time screening; sctMix – Silica Clotting Time mix; sctConf – Silica Clotting Time confirmation; dRVVTscreen – Dilute Russell’s viper venom time screening; dRVVTmix – Dilute Russell’s viper venom time mix; dRVVTconf – Dilute Russell’s viper venom time confirmation)

Representative Thrombin Generation Assay profile of APS patients, asymptomatic aPL+ patients, healthy controls and controls treated with Vitamin K antagonists.
(TGA – Thrombin generation assay; APS – Antiphospholipid Syndrome; aPL – Antiphospholipid antibodies; HC – healthy controls)


Disclosures: M. Radin, None; A. Barinotti, None; I. Cecchi, None; S. Foddai, None; E. Rubini, None; D. Roccatello, None; E. Menegatti, None; S. Sciascia, None.

To cite this abstract in AMA style:

Radin M, Barinotti A, Cecchi I, Foddai S, Rubini E, Roccatello D, Menegatti E, Sciascia S. Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/thrombin-generation-assay-and-lupus-anticoagulant-identify-different-populations-of-patients-with-antiphospholipid-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thrombin-generation-assay-and-lupus-anticoagulant-identify-different-populations-of-patients-with-antiphospholipid-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology